Tag : CVD

  • CONFERENCE UPDATE
    LDL-C reduction with lerodalcibep in patients at very high or high risk for CVD: The phase 3 LIBerate-HR study

    Lerodalcibep is a third-generation proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor that prevents PCSK9 from binding to low-density lipoprotein receptors (LDLRs). Low-density lipoprotein-cholesterol (LDL-C) clearance from the bloodstream is enhanced as a result of LDLR degradation being blocked. Compared to monoclonal antibodies (mAbs), lerodalcibep is smaller in size and has a higher solubility, enabling prolonged and stable LDL-C reductions. In a prior phase 2 trial, lerodalcibep at a dose of 300mg monthly was shown to be effective in lowering LDL-C by >70%.